A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study.In the 393-patient trial, drug candidate rezpegaldesleukin showed a reduction in the ...

Nektar Therapeutics stock launched Tuesday after the biotech company hit every goal in a midstage study of its eczema ...

In trials, Sotyktu was found to be more effective at treating moderate-to-severe psoriasis than Amgen’s PDE4 inhibitor Otezla (apremilast), which was recommended by NICE for a similar patient ...

The CHMP has backed LEO Pharma's delgocitinib for chronic hand eczema, considered to be one of its top pipeline prospects. Skip to main content Sunday 29 June 2025 . BlueSky linkedin youtube rss ...

You've seen plenty of ads for anti-wrinkle creams that promise to make you look years younger and help reduce wrinkles and fine lines. Consumer Reports tests to see if you, too, can have cover ...